An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
AB Gottlieb, B Strober, JG Krueger… - … medical research and …, 2008 - Taylor & Francis
Objective: To evaluate the clinical and biological activity of apremilast in patients with severe
plaque-type psoriasis. Research design and methods: Apremilast, a phosphodiesterase‑4 …
plaque-type psoriasis. Research design and methods: Apremilast, a phosphodiesterase‑4 …
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
AB Gottlieb, RT Matheson, A Menter… - Journal of drugs in …, 2013 - europepmc.org
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability …
M Ohtsuki, Y Okubo, M Komine… - The Journal of …, 2017 - Wiley Online Library
Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, works intracellularly
within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo …
within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo …
[HTML][HTML] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the American …, 2015 - Elsevier
Background Apremilast works intracellularly to regulate inflammatory mediators. Objective
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham… - British Journal of …, 2015 - academic.oup.com
Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo …
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Background Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works
intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and …
intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and …
Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis
T Torres, L Puig - American Journal of clinical dermatology, 2018 - Springer
Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and
negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there …
negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there …
Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
C Pincelli, PH Schafer, LE French… - Journal of drugs in …, 2018 - europepmc.org
Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a
dysregulated immune response. In psoriatic skin, expression of all phosphodiesterase 4 …
dysregulated immune response. In psoriatic skin, expression of all phosphodiesterase 4 …
Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast
M Gooderham, K Papp - BioDrugs, 2015 - Springer
Phosphodiesterase (PDE) 4 participates in regulating the inflammatory response by
degrading cyclic adenosine 3′, 5′-monophosphate (cAMP), a key second messenger …
degrading cyclic adenosine 3′, 5′-monophosphate (cAMP), a key second messenger …
相关搜索
- plaque psoriasis oral phosphodiesterase
- plaque psoriasis safety of apremilast
- open label plaque type
- efficacy of apremilast severe psoriasis
- psoriasis in japan apremilast for patients
- safety of apremilast oral phosphodiesterase
- plaque psoriasis dose comparison
- plaque psoriasis parallel group
- clinical effects apremilast for psoriasis
- japanese patients oral phosphodiesterase
- plaque psoriasis efficacy and safety
- plaque psoriasis apremilast in subjects
- apremilast in the treatment severe psoriasis
- plaque psoriasis japanese patients